Oncotelic Therapeutics, Inc.
OTLC
$0.09
$0.000.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.17% | -216.83% | 43.31% | 42.76% | 62.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -66.44% | -33.79% | -29.07% | -59.54% | 0.92% |
| Total Other Non-Cash Items | -90.52% | 4,896.47% | -49.00% | -47.96% | -66.98% |
| Change in Net Operating Assets | 488.78% | 640.31% | 342.52% | 503.71% | -115.61% |
| Cash from Operations | 30.22% | 51.53% | 48.07% | 43.96% | 1.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 5.36% | -50.13% | -61.23% | -53.48% | 54.25% |
| Total Debt Repaid | -- | -- | -- | -- | -100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 66.67% |
| Cash from Financing | 8.31% | -44.68% | -56.46% | -47.52% | -14.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 318.40% | 114.32% | -7,750.00% | -18.73% | -938.03% |